Sanofi’s latest acquisition sees the group pay $1bn for the private immuno-oncology company Amunix.
Evaluate Vantage's coverage of the Ash 2021 congress.
At a meeting lacking practice-changing studies and featuring many disappointments the downturn in IGM’s fortunes stands out.
Several cell therapy presentations will vie for attention at Ash, though today the spotlight falls on Autolus.
The early movers could point to a disappointing meeting.
Two Xencor approaches with questions around them receive the backing of Johnson & Johnson.
IGM’s snowballing share price belies some other major Ash winners, and will make Christmas unhappy for funds that had shorted the stock.
Evaluate Vantage's coverage of the virtual Ash 2020 congress.
Sellside firefighting has saved the day for IGM, but Ash hears of some pretty potent anti-CD20 competition for the company.